4D Molecular Therapeutics Price Target Maintained With a $40.00/Share by RBC Capital
4D Molecular Therapeutics Price Target Maintained With a $40.00/Share by RBC Capital
RBC资本维持4d分子治疗的目标价为每股40.00美元。
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册